Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL

Abstract: De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To identify such combinations, we previously pe...

Descripció completa

Dades bibliogràfiques

Autors principals:	Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Brian J. Capaldo, Stefan Bekiranov, Mark J. Axelrod, L. Kyle Brett, Julia D. Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2017-06-01
Col·lecció:	Blood Advances
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2473952920302056
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!